MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
← catalyst calendarNCT06586515 · readout ≤ 954 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
630estimated
Sites
52
Countries
Canada, China, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-12 | actual | When the study began enrolling |
| Primary completion | Mar 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Pancreatic Ductal Adenocarcinoma
- Non-small Cell Lung Cancer
- Colorectal Cancer
Interventions
- Drug: LY3962673
- Drug: Cetuximab
- Drug: Gemcitabine
- Drug: nab-paclitaxel
- Drug: Oxaliplatin
- Drug: leucovorin
- Drug: Irinotecan
- Drug: 5-fluorouracil
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
measured Baseline through 5 years
Phase 1a: Number of Participants with DLT
measured During the first 28-day cycle of LY3962673 treatment
Phase 1a: Number of Participants with DLT Equivalent Toxicities
measured During the first 28-day cycle of LY3962673 treatment
Phase 1b: Overall Response Rate (ORR)
measured Up to approximately 5 years
Phase 1b: Best Overall Response (BOR)
measured Up to approximately 5 years
Phase 1b: Duration of Response (DOR)
measured Up to approximately 5 years
Phase 1b: Time to Response (TTR)
measured Up to approximately 5 years
Phase 1b: Disease Control Rate (DCR)
measured Up to approximately 5 years
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed